Malignancies After Heart Transplantation.

Autor:	Stenman C; Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden., Wallinder A; Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden.; Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden., Holmberg E; Regional Cancer Center West, Region Västra Götaland, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Karason K; Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden.; Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.; Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Magnusson J; Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden.; Department of Internal Medicine/Respiratory Medicine and Allergology, Sahlgrenska University Hospital, Gothenburg, Sweden.; Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Dellgren G; Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden.; Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden.; Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Jazyk:	angličtina
Zdroj:	Transplant international : official journal of the European Society for Organ Transplantation [Transpl Int] 2024 Sep 09; Vol. 37, pp. 12109. Date of Electronic Publication: 2024 Sep 09 (Print Publication: 2024).
DOI:	10.3389/ti.2024.12109
Abstrakt:	Heart transplant patients have an increased risk of developing cancer. Patients who underwent HTx between 1985 and 2017 were included. Detection of cancer was obtained by cross-checking the study population with the Swedish Cancer-Registry and the Cause-of-Death-Registry. A total of 664 patients were followed for a median of 7.7 years. In all, 231 malignancies were diagnosed in 138 patients. Compared to the general population the excess risk of cancer following HTx was 6.2-fold calculated as the standardized incidence ratio (SIR) and 2.9-fold after exclusion of non-melanoma skin cancer (NMSC). The most common malignancies were NMSC, non-Hodgins lymphoma, and lung cancer. There was no significant difference in overall survival between those with and without a history of cancer before HTx ( p = 0.53). During a median follow-up of 7.7 years, 19% of HTx recipients developed cancer, 6.2-fold higher relative to the general population, and 2.9-fold higher when excluding NMSC. Risk factors for malignancies (excluding NMSC) included previous smoking, hypertension and prolonged ischemic time; and for NMSC, increasing age, seronegative CMV-donors, and azathioprine. A previous cancer in selected recipients results in similar survival compared to those without cancer prior to HTx. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Stenman, Wallinder, Holmberg, Karason, Magnusson and Dellgren.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu